12 results about "Harmine" patented technology

The invention discloses a pharmaceutical composition for treating pulmonary fibrosis complicated with depression and application of the pharmaceutical composition, and belongs to the field of biological medicine. The pharmaceutical composition provided by the invention comprises harmine and deoxyvasicine, wherein the optimal mass ratio of harmine to deoxyvasicine is 1: 1.25. The curative effect of the pharmaceutical composition is verified by constructing a pulmonary fibrosis and depression combined mouse model, and experimental results show that the pharmaceutical composition provided by the invention can significantly improve the anti-fibrosis effect, can also effectively reduce the neurotoxicity of harmine, shows a synergistic effect, and can be used for preparing anti-fibrosis drugs for treating or preventing the fibrosis. And the curative effect and the safety are both improved. The invention lays a foundation for developing a safe and efficient novel medicine for treating pulmonary fibrosis combined with depression, and has important application value and wide application prospect in treatment of patients with pulmonary fibrosis combined with depression.

The invention relates to the technical field of medicinal chemistry and parasitic disease prevention and treatment, and particularly discloses a novel harmine derivative, a synthesis method and application of the novel harmine derivative to toxoplasma gondii disease resistance. The structural general formula of the derivative is shown in the specification. Wherein R1 is selected from one of hydrogen, C1-4 alkyl, substituted or non-substituted five-membered aryl or six-membered aryl, and substituted or non-substituted five-membered heteroaryl or six-membered heteroaryl containing 1 to 4 heteroatoms selected from N, O or S; r9 is selected from one of hydrogen, substituted or unsubstituted five-membered aryl or six-membered aryl; and R7 is selected from hydrogen, C1-4 alkyl, substituted or unsubstituted five-membered aryl or six-membered aryl. Preferably, the compound is 1-methyl-9-(3-methylpyridine)-beta-carboline-7-ol, and the formula is shown in the description. The novel harmine derivative provided by the invention shows high-efficiency and low-toxicity anti-toxoplasma gondii activity, the synthesis method is simple, and an excellent candidate compound is provided for developing novel anti-toxoplasma gondii drugs.

Provided are human therapeutic compositions including a compound comprising a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compound is a reaction product of an aldehyde and a harmine component. The compositions exhibit anti-cancer properties, particularly against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

The invention belongs to the technical field of chemical synthesis methods, and discloses a synthesis method of beta-carboline compounds. The method comprises the following steps: cyclizing alpha-aminoketone (A) and 3-substituted acrolein (B), reacting the obtained product with hydroxylamine hydrochloride without purification under the catalysis of acid to prepare a 3-aminopyridine derivative, and synthesizing a compound with a beta-carboline structure as shown in a general formula I or a general formula II in the presence of an alkaline reagent or a copper catalyst. According to the method provided by the invention, alpha-aminoketone is taken as a raw material, the beta-carboline compound can be synthesized under a metal-free condition, and the route is short. The synthesis method has a high-efficiency and high-yield synthesis route for natural products, namely harmine and harmine. The synthesis method disclosed by the invention can be used for synthesizing harmine and harmine. The method is simple to operate and high in yield, and provides a new idea for efficient synthesis of the compounds.

The invention discloses a harmine-reinforced nano-modified organosilicon polymer and a preparation method and application thereof.The polymer takes polydimethylsiloxane (PDMS) as a matrix and comprises graphitized multi-walled carbon nanotubes (gMWCNTs) and harmine (PE), the PE is loaded on mesoporous silica (mSiO2) nanoparticles, the PE and mSiO2 are jointly and uniformly dispersed in a PDMS-gMWCNTs (GP) film forming system, and the film forming system is formed by compounding a polydimethylsiloxane film forming system and a harmine film forming system. The content of the gMWCNTs in the nano modified matrix GP is 0.1% (w / w), and the content of the PE in the nano modified matrix GP is 0.5-2.0% (w / w). According to the invention, peganum harmala alkaloid and a carbon nanotube material are utilized to synergistically modify an organic silicon matrix for the first time, so that synchronous improvement of actual marine antifouling efficiency, mechanical strength and ecological safety of the organic silicon polymer is successfully realized.

A composition for administering to a subject includes a first compound chosen from S-5'-adenosyl-L-methionine (SAM), methionine, betaine, choline, folate, vitamin B12, glycine, serine, threonine, and any combination thereof, and a second compound chosen from spermidine, spermine, calcium peroxide, zinc, N-Acetylcysteine, cysteine, α-ketoglutarate, fucoidans, harmine, taurine, ergothioneine, urolithin A, terpenoids, berberine, O3, H2O2, hydrogen sulfide (H2S), sodium hydrosulfide (NaSH), sodium sulfide (Na2S), metformin, acetaminophen, curcumin, quercetin, ginseng, R-alpha-lipoic acid, apigenin, fisetin, melatonin, ginger, astaxanthin methylene blue and optionally, a carrier, and any combination thereof

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.

The invention discloses a novel application of harmine in preparation of thrombolytic drugs. The research shows that harmine can effectively dissolve formed thrombus and relieve vasculopathy, and has the function of protecting blood vessels. After thrombus is formed, harmine is given, and thrombolysis treatment can be achieved through the following steps that the blood flow speed and the blood flow volume of the thrombus part are rapidly recovered; platelet activation and endothelial cell injury are obviously inhibited; and oxidative stress is eliminated. The blood flow disorder caused by thrombus can be quickly improved; formed thrombus is effectively dissolved; the normal vasomotor function is maintained; the physiological hemostasis function is not interfered. The harmine is remarkable in thrombolysis effect and quick in action; the curative effect is lasting; the safety is high and the bleeding risk is low. The invention provides a brand new drug choice for treating thrombotic diseases, and has important clinical application value.

The invention discloses a natural compound for inhibiting disulfide death by taking VAV3 as a target spot and application of the natural compound. Belongs to the technical field of biological medicine and pharmacy. According to the invention, through virtual screening and surface plasmon resonance technologies, seven small molecular compounds, including kaempferol, liensinine, sophocarpidine, isorhamnetin, deoxyshikonin, harmine and potenoside, which can be specifically bound with VAV3 protein are screened from a natural product library for the first time. In a C2C12 cell insulin resistance model, the compounds can significantly reduce the cell death rate caused by disulfide death, and the action mechanism of the compounds is to improve the activity or expression of VAV3, inhibit abnormal accumulation of cystine and improve the NADPH level, thereby effectively preventing disulfide bond crosslinking and collapse of an actin filament network. Experiments show that the compound provided by the invention can effectively inhibit disulfide death of skeletal muscle cells by targeting VAV3, and a new lead compound and a solution are provided for developing drugs for treating diabetic muscle dysfunction and related metabolic diseases.

The present invention relates to a pharmaceutical composition comprising (a) harmine or a pharmaceutically acceptable salt thereof; and (b) N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, wherein the w / w ratio of harmine to N,N-dimethyltryptamine is from 1.2 to 1.4, as well as to a kit of parts comprising (a) harmine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier; and (b) N,N- dimethyltryptamine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; wherein the w / w ratio of harmine to N,N-dimethyltryptamine is from 1.2 to 1.4. The pharmaceutical compositions of the present invention and the kits of parts of the present invention are particularly useful in treating and or preventing psychiatric, psychosomatic or somatic disorders.

The present application relates to the application of harmine in the preparation of a drug for treating CCNE1 amplified ovarian cancer. The cell line of the CCNE1 amplified ovarian cancer is selected from the SKOV3 cell line, the HEY cell line, the A2780 cell line, the OVCAR8 cell line or the OVCAR3 cell line. The present application finds that harmine has significant specific toxicity to CCNE1 amplified ovarian cancer cells. Cell experiments find that the IC50 value of harmine in CCNE1 high expression ovarian cancer cells is significantly lower than that in CCNE1 low expression ovarian cancer cells. Therefore, Haimine can specifically kill CCNE1 amplified ovarian cancer cells, and is expected to become a precise treatment drug for CCNE1 amplified ovarian cancer.

The present invention relates to a composition comprising harmine and (i) an uronic acid or (ii) a carboxylic acid and a monosaccharide, to a salt of harmine and uronic acid, to a kit of parts comprising (a) the composition or the salt of the invention and a pharmaceutically acceptable carrier and (b) DMT or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, to a pharmaceutical composition comprising the composition or the salt of the invention and a pharmaceutically acceptable carrier. The compositions, the salts, the kits of parts and the pharmaceutical compositions of the present invention are particularly useful in the treatment of psychiatric, psychosomatic or somatic disorders.